CHICAGO, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that Zacks Small-Cap Research ("Zacks") has initiated coverage on the Company with a valuation of $4.50 per share, according to a research report published on January 13, 2026 and authored by analyst Brad Sorensen. Zacks highlighted Cosmos Health's diversified revenue base, vertically integrated pharmaceutical and manufacturing operations, technology-enabled initiatives, expansion into the U.S. market, and improving financial performance as key factors supporting its valuation. Key Highlights from Zac

1/14/26 11:25:00 AM ET

$COSM

Other Pharmaceuticals

Health Care

Cosmos Health Enters Manufacturing Agreement with Libytec for PathMuscle Medicine, with Five-Year Volumes Expected to Exceed 1.2 Million Units

CHICAGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its wholly owned subsidiary, Cana Laboratories, has entered into a manufacturing and supply agreement to undertake the full end-to-end production of the pharmaceutical product PathMuscle for Libytec Pharmaceutical S.A., the product's exclusive distributor in Greece. Under the terms of the agreement, Cosmos Health will be responsible for the complete manufacturing of the finished pharmaceutical product, including formulation, production, quality control, and product release, in accordance with appl

1/5/26 9:30:00 AM ET

$COSM

Other Pharmaceuticals

Health Care

Cosmos Health Launches Strategic Partnership With Prime Ledger to Transform $300M Treasury and Tokenize IP Assets

CHICAGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced a long-term strategic partnership with Prime Ledger LLC ("Prime Ledger"), a leading provider of blockchain infrastructure services and digital asset treasury management. This multi-phase agreement is centered on a comprehensive digital transformation of Cosmos Health's financial operations, including participating in the management of its $300,000,000 treasury facility and the tokenization of high-value intellectual property (IP). This collaboration will be executed in several phases, beginning with th

12/3/25 12:20:00 PM ET

$COSM

Other Pharmaceuticals

Health Care

$COSM
Leadership Updates

Live Leadership Updates

View All

Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million

CHICAGO, April 16, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today reported financial results for the full year ended December 31, 2024. Full Year 2024 Financial Highlights Income Statement: FY 2024 performance was marked by revenue growth, an increase in R&D investments, and a substantial reduction in operating expenses, while bottom-line results were impacted by the absence of non-recurring gain

4/16/25 12:45:15 PM ET

$COSM

Other Pharmaceuticals

Health Care

Cosmos Health Strengthens R&D Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology

CHICAGO, IL / ACCESSWIRE / December 26, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology at the Company's Research and Development division.Professor Trafalis currently serves as a Professor of Pharmacology and Clinical Pharmacology at the Faculty of Medicine, National and Kapodistrian University of Athens.He is a medical specialist in onc

12/26/24 1:30:00 PM ET

$COSM

Other Pharmaceuticals

Health Care

Cosmos Health Reports Q3 2023 Results; Revenue Increased 7% YoY, Total Assets Reached Record $71.5M with Stockholders' Equity of $44.2M or $3.4/Share

THESSALONIKI, GREECE / ACCESSWIRE / November 21, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today provided a business update and reported financial results for the third quarter and nine months ended September 30, 2023.Third Quarter 2023 Financial HighlightsRevenues increased to $12.8 million from $12.0 million in Q3 2022, largely due to increased sales attributable to the logistics distribution business, which expanded

11/21/23 9:00:00 AM ET

$COSM

Other Pharmaceuticals

Health Care

$COSM
Financials

Live finance-specific insights

View All

Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000

CHICAGO, April 30, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, has increased his stake in the Company by acquiring a total of 1,466,764 common shares, valued at $526,000, across five transactions between April 21, 2025, and April 24, 2025. As a result of these transactions, Mr. Siokas now beneficially owns 5,582,066 common shares in Cosmos Health. Greg S

4/30/25 12:50:09 PM ET

$COSM

Other Pharmaceuticals

Health Care

Cosmos Health CEO Greg Siokas Acquires a Total of 647,809 Shares Valued at $425,000 Over the Past 32 Days

CHICAGO, IL / ACCESS Newswire / January 21, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, has increased his stake in the Company by acquiring a total of 647,809 common shares, valued at $425,000, across six transactions between December 20, 2024, and January 17, 2025.As a result of these transactions, Mr. Siokas now beneficially owns 4,164,789 common shares in Cosmos Health.Greg Si

1/21/25 3:00:00 PM ET

$COSM

Other Pharmaceuticals

Health Care

Cosmos Health Issues Letter to Shareholders

CHICAGO, IL / ACCESSWIRE / November 12, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its Chief Executive Officer, Greg Siokas, has issued the following letter to the Company's shareholders.Dear Cosmos Health Shareholders,It has been just over a year since my previous shareholder letter, and I would like to express my sincere gratitude for your continued support. We have achieved many positive milestone

11/12/24 12:01:41 PM ET

$COSM

Other Pharmaceuticals

Health Care

SEC Form 4 filed by Cosmos Health Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$COSM

SEC Form 4 filed by Cosmos Health Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$COSM

$COSM
Press Releases

Cosmos Health Announces Initiation of Analyst Coverage with $4.50 Valuation by Zacks Small-Cap Research

Cosmos Health Enters Manufacturing Agreement with Libytec for PathMuscle Medicine, with Five-Year Volumes Expected to Exceed 1.2 Million Units

Cosmos Health Launches Strategic Partnership With Prime Ledger to Transform $300M Treasury and Tokenize IP Assets

$COSM
SEC Filings

Amendment: SEC Form S-3/A filed by Cosmos Health Inc.

SEC Form 424B3 filed by Cosmos Health Inc.

Cosmos Health Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

$COSM
Insider Purchases

Chief Executive Officer Siokas Grigorios bought $220,000 worth of shares (493,495 units at $0.45), increasing direct ownership by 7% to 7,738,474 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $57,000 worth of shares (113,185 units at $0.50), increasing direct ownership by 2% to 7,244,979 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $81,000 worth of shares (156,190 units at $0.52), increasing direct ownership by 2% to 7,131,794 units (SEC Form 4)

$COSM
Insider Trading

Chief Executive Officer Siokas Grigorios bought $220,000 worth of shares (493,495 units at $0.45), increasing direct ownership by 7% to 7,738,474 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $57,000 worth of shares (113,185 units at $0.50), increasing direct ownership by 2% to 7,244,979 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $81,000 worth of shares (156,190 units at $0.52), increasing direct ownership by 2% to 7,131,794 units (SEC Form 4)

$COSM
Leadership Updates

Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million

Cosmos Health Strengthens R&D Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology

Cosmos Health Reports Q3 2023 Results; Revenue Increased 7% YoY, Total Assets Reached Record $71.5M with Stockholders' Equity of $44.2M or $3.4/Share

$COSM
Financials

Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000

Cosmos Health CEO Greg Siokas Acquires a Total of 647,809 Shares Valued at $425,000 Over the Past 32 Days

Cosmos Health Issues Letter to Shareholders

$COSM
Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Cosmos Health Inc.

SEC Form SC 13G filed by Cosmos Health Inc.

SEC Form SC 13D/A filed by Cosmos Health Inc. (Amendment)

SEC Form 4 filed by Cosmos Health Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $COSM

SEC Form 4 filed by Cosmos Health Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $COSM

$COSM Press Releases

Cosmos Health Announces Initiation of Analyst Coverage with $4.50 Valuation by Zacks Small-Cap Research

Cosmos Health Enters Manufacturing Agreement with Libytec for PathMuscle Medicine, with Five-Year Volumes Expected to Exceed 1.2 Million Units

Cosmos Health Launches Strategic Partnership With Prime Ledger to Transform $300M Treasury and Tokenize IP Assets

$COSM SEC Filings

Amendment: SEC Form S-3/A filed by Cosmos Health Inc.

SEC Form 424B3 filed by Cosmos Health Inc.

Cosmos Health Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

$COSM Insider Purchases

Chief Executive Officer Siokas Grigorios bought $220,000 worth of shares (493,495 units at $0.45), increasing direct ownership by 7% to 7,738,474 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $57,000 worth of shares (113,185 units at $0.50), increasing direct ownership by 2% to 7,244,979 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $81,000 worth of shares (156,190 units at $0.52), increasing direct ownership by 2% to 7,131,794 units (SEC Form 4)

$COSM Insider Trading

Chief Executive Officer Siokas Grigorios bought $220,000 worth of shares (493,495 units at $0.45), increasing direct ownership by 7% to 7,738,474 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $57,000 worth of shares (113,185 units at $0.50), increasing direct ownership by 2% to 7,244,979 units (SEC Form 4)

Chief Executive Officer Siokas Grigorios bought $81,000 worth of shares (156,190 units at $0.52), increasing direct ownership by 2% to 7,131,794 units (SEC Form 4)

$COSM Leadership Updates

Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million

Cosmos Health Strengthens R&D Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology

Cosmos Health Reports Q3 2023 Results; Revenue Increased 7% YoY, Total Assets Reached Record $71.5M with Stockholders' Equity of $44.2M or $3.4/Share

$COSM Financials

Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000

Cosmos Health CEO Greg Siokas Acquires a Total of 647,809 Shares Valued at $425,000 Over the Past 32 Days

Cosmos Health Issues Letter to Shareholders

$COSM Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Cosmos Health Inc.

SEC Form SC 13G filed by Cosmos Health Inc.

SEC Form SC 13D/A filed by Cosmos Health Inc. (Amendment)

Recent Analyst Ratings for
$COSM

Recent Analyst Ratings for
$COSM

$COSM
Press Releases

$COSM
SEC Filings

$COSM
Insider Purchases

$COSM
Insider Trading

$COSM
Leadership Updates

$COSM
Financials

$COSM
Large Ownership Changes